Ceritinib

CHEMBL2403108 Phase 4 Aprovado Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

558.1 g/mol

LogP

6.4

Phase

4

A kinase inhibitor targeting anaplastic lymphoma kinase (ALK) and other related kinases, used in the treatment of ALK-positive non-small cell lung cancer, particularly after progression on or intolerance to crizotinib. It penetrates the central nervous system and can treat brain metastases. Gastrointestinal side effects are common, and taking it with a low-fat meal helps reduce tolerability issues.

Peso Molecular

558,1000 g/mol

LogP

6,40

TPSA

114,00 Å²

Regra dos 5 de Lipinski

Reprovado

Áreas Terapêuticas

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Melanoma Lymphoma Breast Cancer Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Estrutura 2D

SVG PNG

Cite this structure

Embed this structure

SMILES

Cc1cc(Nc2ncc(Cl)c(Nc3ccccc3S(=O)(=O)C(C)C)n2)c(OC(C)C)cc1C1CCNCC1

InChI

InChI=1S/C28H36ClN5O3S/c1-17(2)37-25-15-21(20-10-12-30-13-11-20)19(5)14-24(25)33-28-31-16-22(29)27(34-28)32-23-8-6-7-9-26(23)38(35,36)18(3)4/h6-9,14-18,20,30H,10-13H2,1-5H3,(H2,31,32,33,34)

Molecular Formula

C28H36ClN5O3S

HBD / HBA

3 / 8

Ligações Rotacionáveis

9

Átomos Pesados

38

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A kinase inhibitor targeting anaplastic lymphoma kinase (ALK) and other related kinases, used in the treatment of ALK-positive non-small cell lung cancer, particularly after progression on or intolerance to crizotinib. It penetrates the central nervous system and can treat brain metastases. Gastrointestinal side effects are common, and taking it with a low-fat meal helps reduce tolerability issues.

Yes, Ceritinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2403108. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 57379345. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Procura informações acessíveis para o paciente?

Ceritinib no PillFYI

Estrutura

Dados Rápidos

Fórmula: C28H36ClN5O3S
Sinônimos: 1

Links Externos

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.